Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Filings indexed 249 across all filing types
Latest filing 2022-03-03 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
Annual information form - English.pdf
Regulatory Filings
2022-03-03 English
News release - English.pdf
Investor Presentation Classification · 70% confidence The document is a press release announcing PsyBio Therapeutics' participation in Citi's Psychedelic Drug Video Call Series. It includes details about the event, company background, and contact information. There is no financial data, report content, or regulatory filing referenced. The document is an announcement of an investor-related event rather than a financial report or regulatory filing. It does not fit into categories like earnings release, annual report, or management report. The best fitting category is Investor Presentation (IP) because it is a detailed presentation for investors focusing on company strategy and market position, even though it is an announcement of participation rather than the presentation itself. Given the short length and nature, confidence is moderate.
2022-02-02 English
News release - English.pdf
Regulatory Filings
2022-01-10 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the establishment of a research and development laboratory by PsyBio Therapeutics and the expansion of its collaboration with Miami University. It discusses the company's research activities, future plans for drug development, and regulatory intentions such as filing an Investigational New Drug (IND) application with the FDA. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on corporate developments and research progress rather than financial results or regulatory filings. It is not a report, audit, earnings release, or any form of regulatory filing. The document is best classified as a general regulatory announcement or corporate update that does not fit into more specific categories like capital updates or management changes. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2022-01-05 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a pre-IND meeting with the FDA by PsyBio Therapeutics. It discusses regulatory interactions and future plans for drug development but does not contain any financial data, financial statements, or detailed financial analysis. It is not a report, transcript, or regulatory filing but rather a corporate announcement about regulatory progress. The content is consistent with a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length is about 9000 characters, which is typical for a press release. Therefore, the best classification is Regulatory Filings (RNS).
2021-12-07 English
News release - English.pdf
Regulatory Filings
2021-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.